VALNEVA (EPA:VLA) | Finanzwire

Basculer en Français

10230	Companies
211156	Keywords
141075	Articles
111857	Press releases

Home
Companies
VALNEVA

BRIEF

published on 03/31/2026 at 14:30, 16 days 14 hours ago

Valneva's Lyme Disease Vaccine Shows Promise Despite Missed Trial Endpoint

FDA Approval Price Target Phase 3 Trial Valneva SE Lyme Disease Vaccine
PRESS RELEASE

published on 03/31/2026 at 14:25, 16 days 14 hours ago

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates Valneva SE (FR0004056851) analysis post Lyme phase 3 trial topline results with Pfizer. Despite missing primary endpoint, optimism remains for FDA approval

FDA Approval First Berlin Equity Research Valneva SE Pfizer Lyme Vaccine
BRIEF

published on 03/26/2026 at 17:50, 21 days 10 hours ago

Valneva at the 25th World Vaccine Congress in Washington

Valneva World Vaccine Congress Clinical Studies Vaccination Chikungunya
BRIEF

published on 03/23/2026 at 12:22, 24 days 16 hours ago

Pfizer and Valneva unveil promising results for their Lyme disease vaccine

Valneva Vaccine Phase 3 Pfizer Lyme
BRIEF

published on 02/20/2026 at 12:01, 1 month 24 days ago

Valneva SE: Research Update and Financial Projections

Valneva SE Financial Update Lyme Vaccine Third-Party Sales Target Price Adjustments
PRESS RELEASE

published on 02/20/2026 at 11:56, 1 month 24 days ago

Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH updated Valneva SE's classification to Buy with a target price of €6.60. Details on 2025 revenues, cash figures, and 2026 guidance included

Buy Recommendation Valneva SE First Berlin Equity Research GmbH 2025 Revenues 2026 Guidance
BRIEF

published on 01/09/2026 at 07:05, 3 months 7 days ago

Valneva Engages Investors at J.P. Morgan Healthcare Conference

Valneva Investor Meetings Lyme Disease Vaccine J.P. Morgan Conference Vaccine Portfolio
PRESS RELEASE

published on 01/09/2026 at 07:00, 3 months 7 days ago

Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
Valneva SE to meet with investors at the J.P. Morgan Healthcare Conference to discuss upcoming catalysts from its clinical development pipeline and commercial portfolio of vaccines. Company specializes in prophylactic vaccines for infectious diseases

Valneva SE Prophylactic Vaccines J.P. Morgan Healthcare Conference Vaccine Company Clinical Development Pipeline
BRIEF

published on 12/31/2025 at 17:50, 3 months 16 days ago

Valneva and Serum Institute End Chikungunya Vaccine Collaboration

Public Health Valneva License Agreement Chikungunya Vaccine Serum Institute
PRESS RELEASE

published on 12/31/2025 at 17:45, 3 months 16 days ago

Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
Valneva and Serum Institute of India mutually agree to discontinue chikungunya vaccine license. Valneva aims for direct control over supply chain and access to high-risk regions

Valneva License Agreement CEPI Chikungunya Vaccine Serum Institute Of India

Accesswire

Published on 04/17/2026 at 02:13, 2 hours 27 minutes ago

CHAR Tech annonce l’acquisition projetée d’actifs de biocarbone au Québec, incluant un accord d’achat de 62 500 tonnes, une installation et de la propriété intellectuelle
Published on 04/17/2026 at 02:00, 2 hours 40 minutes ago

UraniumX Announces Closing Of Final Tranche Of Non-Brokered Private Placement
Published on 04/16/2026 at 23:32, 5 hours 8 minutes ago

Zomedica Announces “Fourth Friday at Four” Webinar on April 24th: A Behind-the-Scenes Look at Manufacturing Excellence and Operational Scale
Published on 04/16/2026 at 21:30, 7 hours 10 minutes ago

Organto Foods Expands Financing Facilities with Rabobank
Published on 04/16/2026 at 15:55, 12 hours 45 minutes ago

TripSitter Announces Director Resignation

View all ACCESSWIRE

EQS Group

Published on 04/16/2026 at 23:40, 4 hours 59 minutes ago

Coventry Ranks #1 in 2025 Life Settlement League Table Report
Published on 04/16/2026 at 21:37, 7 hours 2 minutes ago

Approval of the Offer Document concerning the voluntary tender offer for shares of NEXT RE SIIQ S.p.A.
Published on 04/16/2026 at 21:00, 7 hours 39 minutes ago

Vizrt AI Keyer kills the green screen and creates virtual scenes in any environment
Published on 04/16/2026 at 20:35, 8 hours 4 minutes ago

EQS-Adhoc: Correction of a release from 16/04/2026, 19:17 CET/CEST - Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
Published on 04/16/2026 at 19:17, 9 hours 22 minutes ago

EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year

Les Echos

Published on 04/16/2026 at 18:02, 10 hours 38 minutes ago

Covivio - Description of the share buy-back program authorized by the Combined Ordinary and Extraordinary Shareholders’ Meeting held on 16 April 2026
Published on 04/16/2026 at 18:00, 10 hours 40 minutes ago

ICADE – PR – Q1 2026 TRADING UPDATE
Published on 04/16/2026 at 17:55, 10 hours 45 minutes ago

Publication of 2026 1st quarter turnover
Published on 04/16/2026 at 17:54, 10 hours 46 minutes ago

Aéroports de Paris S.A - March 2026 traffic figures
Published on 04/16/2026 at 17:45, 10 hours 55 minutes ago

VOGO : 2025 full-year results.

View all LES ECHOS COMFI WIRE